About Imon Ghosh

Imon is an investment analyst and journalist with an enthusiasm for financial research and writing. She began her career at Kantar IMRB, a leading market research and consumer consulting organization. Imon studied St. Xavier's University, where she majored in Economics and wrote her academic thesis on inflation and the stock market.

Recent Articles By Imon Ghosh

: AMD |  News, Ratings, and Charts

Advanced Micro Devices vs. Synopsys: Which Semiconductor Stock is a Better Buy?

As technical innovations in energy, automotive and artificial intelligence continue at an unprecedented pace, semiconductors have emerged as an absolute necessity across many industries. As demand for semiconductors from car makers to consumer electronics has increased sharply, we think Advanced Micro Devices (AMD) and Synopsys (SNPS) are poised for significant growth this year and beyond. But let’s find out which of these stocks is a better buy now. Read on.
: TDOC |  News, Ratings, and Charts

After Reporting Q2 Earnings, is Teladoc Health a Buy?

The share price of whole-person virtual care operator Teladoc Health (TDOC) has tumbled owing to its unimpressive second-quarter earnings. Although the company’s personalized virtual care offerings should bode well for the stock, we think the company's high valuation and widening losses in the face of stiff competition could cause its shares to decline further. Read more to find out.
: FL |  News, Ratings, and Charts

3 Red-Hot Momentum Stocks That Are Still Dirt Cheap

As concerns over a surge in inflation, rising COVID-19 cases, and a potential slowdown in economic activities continue to spook investors, it may not be smooth sailing ahead for the stock market. Amid this volatile environment, we think it is safer to focus on stocks that are maintaining strong momentum, while trading at relatively affordable prices. Thus, we believe cheap momentum stocks Foot Locker (FL), Signet Jewelers (SIG), and Guess? (GES) are solid picks now. Read on.
: ACB |  News, Ratings, and Charts

Is Aurora Cannabis a Buy Under $8?

Currently trading at $7.02, Canada-based cannabis operator Aurora Cannabis (ACB) has been expanding its portfolio and making significant advances in the international medical business. However, the company has been struggling to generate revenue growth in the consumer cannabis market. In addition, since there are still substantial hurdles to federal-level legalization of cannabis, is ACB a risky bet now? Read more to find out.
: VTRS |  News, Ratings, and Charts

Is Viatris a Winner in the Pharmaceuticals Industry?

Healthcare company Viatris (VTRS) grabbed investors’ attention when its first interchangeable biosimilar drug received FDA approval recently. However, given that it could still be some time before VTRS becomes a viable growth company, is the stock worth betting on now? Let’s find out.
: SAP |  News, Ratings, and Charts

Why SAP Belongs in Your Portfolio

Enterprise software provider SAP SE (SAP) continues to witness strong sales momentum as its ‘RISE with SAP’ offering gains increasing market traction. Consequently, the company has raised its 2021 outlook. With more organizations adopting SAP’s cloud solutions, we believe the stock has plenty more upside to deliver. Let’s discuss
: UNH |  News, Ratings, and Charts

Will UnitedHealth Group Remain at the Top of the Healthcare Sector?

Leading health insurance provider UnitedHealth Group (UNH) has witnessed accelerated revenue growth across all its business segments in its last reported quarter. Given the company’s solid financials and strategic collaborations, let’s evaluate if the stock is a top player in the healthcare industry. Read on.
: CLOV |  News, Ratings, and Charts

Is Clover Health a Risky Investment?

Healthcare technology company Clover Health Investments’ (CLOV) stock price hit new highs earlier last month, propelled by the meme-stock frenzy. However, given the stock’s ebbing momentum, is it a safe pick now? Let’s find out.
: CROX |  News, Ratings, and Charts

Is Crocs Stock a Buy or a Sell?

Casual footwear giant Crocs’ (CROX) stellar quarterly performance and innovative product collection have captivated investors. However, given that its signature clog is facing design infringement issues by copycat footwear, is the stock worth betting on now? Read on.
: DGX |  News, Ratings, and Charts

Will Quest Diagnostics Stock Continue to Climb?

The share price of leading diagnostic information services provider Quest Diagnostics (DGX) has been surging as the spread of the COVID-19 Delta variant across the United States increases COVID-19 testing volume. However, given its uncertain growth outlook and the growing competition in the COVID-19 diagnostic testing space, can the stock keep rallying? Let’s discuss.
Page generated in 0.5213 seconds.